Welcome to your Saturday Biotech & Pharma Stock Market Recap

What’s to be covered in this hallowed scroll:

1. Overview of the biotech & pharma stocks that had the best & worst weeks (as measured by % change in price)

2. We’ll give you a calendar of whose announcing earnings in the upcoming week - and if they’re before the markets open (BMO) or after markets close (AMC).

3. One more thing we’ll have in future weeks - a recap of the more notable earnings calls the week previous.

Lastly - all three of the above will have sub-sections divided by:

1. Biotechnology (life sciences and the like)

2. Drug Manufacturers - General (this one includes big pharma)

3. Drug Manufacturers - Specialty and Pharma (everyone else that makes drugs, and then some)

And last thing - everything is in USD unless otherwise stated!

This weekend edition is a new feature at TLDR Biotech, so I’d love to get your feedback.

(You can also reach out to me on LinkedIn)

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team!).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

Biotechnology

For the winners - Galera Therapeutics’ (GRTX) microcap jumped on no news in particular.

On the more rational side, CASI Pharmaceuticals (CASI) jumped on financing news, while and Carisma Therapeutics (CARM) nearly doubled on good news from their collab with Moderna (MRNA).

For the losers - eFFECTOR Therapeutics (EFTR) cratered as the company is winding down, while Allarity Therapeutics (ALLR) got called out by NASDAQ for non-compliance.

And though X4 Pharmaceuticals (XFOR) released some positive data this week, their stock still stumbled.

Upcoming Biotechnology Earnings Calls

No earnings call next week for this group!

Instead, why not learn about worm-derived therapies? (Not sponsored!)

AFFILIATE
Finviz: ✨Financial Visualizations🤩

I’m using Finviz to put together these compilations - it’s the easiest way to visualize and assess multiple stocks within the same industry (like within biotech).

If this is down your alley, you can check it out for free using my Affiliate link.

Drug Manufacturers - General

Scilex (SCLX) AGAIN tops the leader board, sitting pretty for a third week (maybe on this news?) - will we see them make a positive YTD return?

Biogen (BIIB) bump-up might be on news of their Alzheimer’s med Leqembi finally launching in China.

On the losers side - Grifols (GRFS) slid due to a downgraded credit ranking, while Mira Pharmaceuticals (MIRA) may have dropped due to a potentially distracted CFO.

Upcoming Drug Manufacturers - General Earnings Calls

No earnings next week for this week group!

Instead, why not consider ditching that daily multivitamin?

Drug Manufacturers - Specialty & Generic

Alimera Sciences (ALIM) jumped on acquisition news, while Eagle Pharmaceuticals (EGRX) has been on a rebound since the end of May (on no particular news, so this might not be a continuing trend - and their 1-year chart doesn’t bring much hope).

For Sunshine Biopharma (SBFM), considering its precipitous plunge, their gap-up might be a dead cat bounce.

For the losers - for Lucy Scientific Discovery (LSDI), the drop is likely part of a correction from a mid-May speculative surge - checking the YTD chart, it’s now given up all those aforementioned gains.

For Elanco Animal Health, an unexpected box label warning for an upcoming commercial asset likely spooked investors, sending the stock lower.

Upcoming Drug Manufacturers - Specialty & Generic Earnings Calls

No earnings next week for this week group!

Instead, why not learn about the history of the stock ticker?

That’s all for now - go enjoy your weekend!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of 500+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here